NASDAQ:CMPS

COMPASS Pathways Competitors

$34.35
+0.32 (+0.94 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$33.92
Now: $34.35
$35.18
50-Day Range
$34.75
MA: $39.71
$50.11
52-Week Range
$22.51
Now: $34.35
$61.69
Volume308,409 shs
Average Volume394,836 shs
Market Capitalization$1.26 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

COMPASS Pathways (NASDAQ:CMPS) Vs. BHVN, SAGE, HCM, EBS, IMAB, and ARNA

Should you be buying CMPS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to COMPASS Pathways, including Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), Emergent BioSolutions (EBS), I-Mab (IMAB), and Arena Pharmaceuticals (ARNA).

COMPASS Pathways (NASDAQ:CMPS) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Profitability

This table compares COMPASS Pathways and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
COMPASS PathwaysN/AN/AN/A
Biohaven PharmaceuticalN/A-1,091.41%-120.85%

Analyst Ratings

This is a summary of current ratings and price targets for COMPASS Pathways and Biohaven Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
COMPASS Pathways00603.00
Biohaven Pharmaceutical021002.83

COMPASS Pathways presently has a consensus target price of $70.75, suggesting a potential upside of 105.97%. Biohaven Pharmaceutical has a consensus target price of $96.4545, suggesting a potential upside of 29.37%. Given COMPASS Pathways' stronger consensus rating and higher possible upside, equities research analysts clearly believe COMPASS Pathways is more favorable than Biohaven Pharmaceutical.

Institutional & Insider Ownership

15.8% of COMPASS Pathways shares are held by institutional investors. Comparatively, 99.4% of Biohaven Pharmaceutical shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares COMPASS Pathways and Biohaven Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.83

Summary

COMPASS Pathways beats Biohaven Pharmaceutical on 5 of the 8 factors compared between the two stocks.

Sage Therapeutics (NASDAQ:SAGE) and COMPASS Pathways (NASDAQ:CMPS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Sage Therapeutics and COMPASS Pathways' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sage Therapeutics$6.87 million646.96$-680,240,000.00($13.38)-5.69
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A

COMPASS Pathways has lower revenue, but higher earnings than Sage Therapeutics.

Analyst Recommendations

This is a summary of current recommendations and price targets for Sage Therapeutics and COMPASS Pathways, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sage Therapeutics08802.50
COMPASS Pathways00603.00

Sage Therapeutics presently has a consensus price target of $87.0625, indicating a potential upside of 14.36%. COMPASS Pathways has a consensus price target of $70.75, indicating a potential upside of 105.97%. Given COMPASS Pathways' stronger consensus rating and higher probable upside, analysts plainly believe COMPASS Pathways is more favorable than Sage Therapeutics.

Institutional & Insider Ownership

15.8% of COMPASS Pathways shares are held by institutional investors. 4.8% of Sage Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Sage Therapeutics and COMPASS Pathways' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sage Therapeutics-7,706.84%-63.81%-56.64%
COMPASS PathwaysN/AN/AN/A

Summary

COMPASS Pathways beats Sage Therapeutics on 7 of the 10 factors compared between the two stocks.

Hutchison China MediTech (NASDAQ:HCM) and COMPASS Pathways (NASDAQ:CMPS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Profitability

This table compares Hutchison China MediTech and COMPASS Pathways' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
COMPASS PathwaysN/AN/AN/A

Earnings and Valuation

This table compares Hutchison China MediTech and COMPASS Pathways' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech$204.89 million20.65$-106,020,000.00($0.80)-36.33
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A

COMPASS Pathways has lower revenue, but higher earnings than Hutchison China MediTech.

Insider and Institutional Ownership

33.5% of Hutchison China MediTech shares are owned by institutional investors. Comparatively, 15.8% of COMPASS Pathways shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Hutchison China MediTech and COMPASS Pathways, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech00203.00
COMPASS Pathways00603.00

Hutchison China MediTech presently has a consensus target price of $40.00, indicating a potential upside of 37.65%. COMPASS Pathways has a consensus target price of $70.75, indicating a potential upside of 105.97%. Given COMPASS Pathways' higher possible upside, analysts clearly believe COMPASS Pathways is more favorable than Hutchison China MediTech.

Summary

COMPASS Pathways beats Hutchison China MediTech on 3 of the 5 factors compared between the two stocks.

COMPASS Pathways (NASDAQ:CMPS) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Profitability

This table compares COMPASS Pathways and Emergent BioSolutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
COMPASS PathwaysN/AN/AN/A
Emergent BioSolutions12.50%26.68%12.70%

Valuation & Earnings

This table compares COMPASS Pathways and Emergent BioSolutions' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A
Emergent BioSolutions$1.11 billion3.76$54.50 million$2.9126.68

Emergent BioSolutions has higher revenue and earnings than COMPASS Pathways.

Insider and Institutional Ownership

15.8% of COMPASS Pathways shares are held by institutional investors. Comparatively, 80.2% of Emergent BioSolutions shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for COMPASS Pathways and Emergent BioSolutions, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
COMPASS Pathways00603.00
Emergent BioSolutions02502.71

COMPASS Pathways presently has a consensus price target of $70.75, suggesting a potential upside of 105.97%. Emergent BioSolutions has a consensus price target of $113.6667, suggesting a potential upside of 46.40%. Given COMPASS Pathways' stronger consensus rating and higher probable upside, analysts plainly believe COMPASS Pathways is more favorable than Emergent BioSolutions.

Summary

Emergent BioSolutions beats COMPASS Pathways on 7 of the 10 factors compared between the two stocks.

I-Mab (NASDAQ:IMAB) and COMPASS Pathways (NASDAQ:CMPS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for I-Mab and COMPASS Pathways, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
I-Mab00403.00
COMPASS Pathways00603.00

I-Mab presently has a consensus target price of $70.00, suggesting a potential upside of 22.81%. COMPASS Pathways has a consensus target price of $70.75, suggesting a potential upside of 105.97%. Given COMPASS Pathways' higher possible upside, analysts plainly believe COMPASS Pathways is more favorable than I-Mab.

Valuation and Earnings

This table compares I-Mab and COMPASS Pathways' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
I-Mab$4.31 million951.50$-208,560,000.00($28.90)-1.97
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A

COMPASS Pathways has lower revenue, but higher earnings than I-Mab.

Institutional & Insider Ownership

16.6% of I-Mab shares are owned by institutional investors. Comparatively, 15.8% of COMPASS Pathways shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares I-Mab and COMPASS Pathways' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
I-MabN/AN/AN/A
COMPASS PathwaysN/AN/AN/A

Summary

COMPASS Pathways beats I-Mab on 3 of the 5 factors compared between the two stocks.

Arena Pharmaceuticals (NASDAQ:ARNA) and COMPASS Pathways (NASDAQ:CMPS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Arena Pharmaceuticals and COMPASS Pathways, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arena Pharmaceuticals001503.00
COMPASS Pathways00603.00

Arena Pharmaceuticals presently has a consensus target price of $92.80, indicating a potential upside of 38.34%. COMPASS Pathways has a consensus target price of $70.75, indicating a potential upside of 105.97%. Given COMPASS Pathways' higher probable upside, analysts clearly believe COMPASS Pathways is more favorable than Arena Pharmaceuticals.

Earnings and Valuation

This table compares Arena Pharmaceuticals and COMPASS Pathways' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arena Pharmaceuticals$806.43 million5.02$397.55 million$7.698.72
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A

Arena Pharmaceuticals has higher revenue and earnings than COMPASS Pathways.

Profitability

This table compares Arena Pharmaceuticals and COMPASS Pathways' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arena PharmaceuticalsN/A-33.17%-30.41%
COMPASS PathwaysN/AN/AN/A

Institutional and Insider Ownership

89.7% of Arena Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.8% of COMPASS Pathways shares are owned by institutional investors. 3.1% of Arena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Arena Pharmaceuticals beats COMPASS Pathways on 5 of the 8 factors compared between the two stocks.


COMPASS Pathways Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.56+1.7%$4.70 billionN/A-6.08Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.13+0.8%$4.41 billion$6.87 million-7.36Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.06+1.1%$4.28 billion$204.89 million-36.33
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64+4.1%$4.16 billion$1.11 billion24.96Analyst Report
I-Mab logo
IMAB
I-Mab
1.2$57.00+0.2%$4.11 billion$4.31 million-1.97Increase in Short Interest
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.08+1.4%$4.10 billion$806.43 million-9.50Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.28+1.4%$3.84 billion$117.91 million-11.01
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.83+2.6%$3.81 billionN/A0.00Analyst Report
Increase in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.74+4.7%$3.78 billionN/A-21.01Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57+1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.11+1.3%$3.53 billion$114.62 million-7.71Analyst Report
Insmed logo
INSM
Insmed
1.2$32.62+3.1%$3.47 billion$136.47 million-12.55
LEGN
Legend Biotech
1.2$26.00+0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.14+0.3%$3.39 billion$339.08 million-12.29Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.96+1.6%$3.39 billion$306.98 million-7.00
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87+1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.37+0.5%$3.29 billion$36.13 million-70.70
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$113.23+3.6%$3.17 billionN/A-56.33Insider Selling
Arvinas logo
ARVN
Arvinas
1.5$64.69+2.6%$3.16 billion$42.98 million-25.27
Alkermes logo
ALKS
Alkermes
1.2$19.65+0.6%$3.15 billion$1.17 billion-42.72
MorphoSys logo
MOR
MorphoSys
0.3$22.75+1.9%$3.05 billion$80.43 million108.34Decrease in Short Interest
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$62.88+5.5%$2.91 billion$421.03 million22.14Analyst Report
Insider Selling
News Coverage
Gap Up
OPKO Health logo
OPK
OPKO Health
1.9$4.27+1.2%$2.89 billion$901.90 million-23.72
Organogenesis logo
ORGO
Organogenesis
1.0$21.22+6.5%$2.89 billion$260.98 million-353.67
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.43+1.3%$2.85 billion$644.77 million-10.76
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.10+2.3%$2.73 billion$182.24 million-8.78Analyst Upgrade
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.18+4.5%$2.72 billion$25 million-9.04Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.67+0.3%$2.71 billionN/A-23.99
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.50+2.0%$2.69 billion$306.49 million25.28
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.28+3.4%$2.62 billion$60,000.00-9.71
Xencor logo
XNCR
Xencor
1.2$42.78+4.4%$2.59 billion$156.70 million-30.56
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.88+1.1%$2.57 billion$2.11 million-8.85Analyst Report
Analyst Revision
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23+0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.76+3.6%$2.48 billion$15 million-17.68Unusual Options Activity
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.50+0.2%$2.42 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$50.89+4.0%$2.41 billion$33.94 million-87.74Gap Up
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.96+0.2%$2.25 billion$963.01 million13.96
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.33+2.7%$2.18 billion$23.90 million-18.22Analyst Report
Unusual Options Activity
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$49.10+2.4%$2.06 billionN/A0.00Insider Selling
Analyst Revision
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$123.42+2.6%$2.03 billionN/A-11.15
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.52+2.2%$2.00 billion$103.54 million-19.19Insider Selling
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$60.11+3.8%$2.00 billionN/A-25.58Increase in Short Interest
Amarin logo
AMRN
Amarin
1.6$5.02+0.2%$1.98 billion$429.76 million-100.38Analyst Revision
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.15+0.9%$1.97 billionN/A-19.39
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$21.39+3.5%$1.96 billion$34.51 million-18.28Gap Down
MacroGenics logo
MGNX
MacroGenics
1.2$31.60+3.2%$1.95 billion$64.19 million-10.10Decrease in Short Interest
News Coverage
Kura Oncology logo
KURA
Kura Oncology
1.6$28.84+2.2%$1.95 billionN/A-17.69
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.22+3.5%$1.94 billion$410,000.00-5.92Analyst Report
MORF
Morphic
1.3$54.52+1.6%$1.80 billion$16.98 million-34.95Insider Selling
Decrease in Short Interest
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.57+1.2%$1.78 billion$26.87 million-12.86Insider Selling
Gap Up
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.